What does PHARMA 2424 do?

PHARMA 2424 is a pharmacy in Charleroi. Private Limited, started on 23 December 2011, 2 establishments.

What is the address of PHARMA 2424?

The registered office of PHARMA 2424 is located at Rue Neuve 1, 6061 Charleroi.

Is PHARMA 2424 still active?

Yes. According to the CBE (29 October 2026) PHARMA 2424 is active, legal situation “Normale toestand”, started on 23 December 2011.

Is PHARMA 2424 registered on Peppol?

Yes, PHARMA 2424 is registered on the Peppol network with ID 0208:0842084219.

What is the enterprise number of PHARMA 2424?

The enterprise number of PHARMA 2424 is BE0842084219.

When was PHARMA 2424 founded?

PHARMA 2424 was founded on 23 December 2011.

Who are the directors of PHARMA 2424?

According to the 2025 annual accounts, the directors of PHARMA 2424 are: Christiane Delfosse Sabine, Didier TENRET.

Is PHARMA 2424 a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 23 December 2011; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account; 2 establishments in the CBE.

How much profit did PHARMA 2424 make in 2025?

PHARMA 2424 posted a profit after taxes of € 56,862 in financial year 2025.

What is the revenue of PHARMA 2424?

As a small company, PHARMA 2424 is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 195,539.

How much does an employee at PHARMA 2424 earn?

The average wage cost per full-time employee at PHARMA 2424 was € 44,400 in 2025: staff costs of € 48,856 for 1.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMA 2424 have?

According to the 2025 annual accounts, PHARMA 2424 has 1.1 full-time equivalents (FTE).

PHARMA 2424 (Private Limited) - Charleroi - BE0842084219

Dossier PHARMA 2424, printed on 29 October 2026 from databakkes.be/en/0842084219/pharma-2424. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARMA 2424 from Charleroi, company number BE0842084219, closed financial year 2025 with a result of € 56,862 after tax. For that financial year PHARMA 2424 recorded a gross margin of € 195,539 and equity of € 304,601. Compared with financial year 2024, the result moved from € 55,196 to € 56,862. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 7, 2026.

What it is worth Growing

€ 304,601

▲ 23% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 56,862

▲ 3% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 70,643

▼ 49% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 284,601.

People and assets in 2025

Full-time equivalents

1.1

▼ 0.3 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 48,856

▼ 3% vs 2024

€ 44,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 10,828

▼ 51% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 187,842

▼ 31% vs 2024

€ 77,121 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 36,825

▼ 4% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 18,240

▼ 14% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 221,292 Gross margin 2022: € 221,292 First fiscal year in the series	€ 190,819 Gross margin 2023: € 190,819 ▼ 14% vs 2022 (€ 221,292) Unfavourable step	€ 196,925 Gross margin 2024: € 196,925 ▲ 3% vs 2023 (€ 190,819) Favourable step	€ 195,539 Gross margin 2025: € 195,539 ▼ 1% vs 2024 (€ 196,925) Unfavourable step	▼ 1%
Profit after taxes	€ 60,580 Profit after taxes 2022: € 60,580 First fiscal year in the series	€ 58,401 Profit after taxes 2023: € 58,401 ▼ 4% vs 2022 (€ 60,580) Unfavourable step	€ 55,196 Profit after taxes 2024: € 55,196 ▼ 5% vs 2023 (€ 58,401) Unfavourable step	€ 56,862 Profit after taxes 2025: € 56,862 ▲ 3% vs 2024 (€ 55,196) Favourable step	▲ 3%
Equity	€ 195,343 Equity 2022: € 195,343 First fiscal year in the series	€ 253,743 Equity 2023: € 253,743 ▲ 30% vs 2022 (€ 195,343) Favourable step	€ 247,740 Equity 2024: € 247,740 ▼ 2% vs 2023 (€ 253,743) Unfavourable step	€ 304,601 Equity 2025: € 304,601 ▲ 23% vs 2024 (€ 247,740) Favourable step	▲ 23%
Total debts	€ 485,882 Total debts 2022: € 485,882 First fiscal year in the series	€ 397,874 Total debts 2023: € 397,874 ▼ 18% vs 2022 (€ 485,882) Favourable step	€ 360,802 Total debts 2024: € 360,802 ▼ 9% vs 2023 (€ 397,874) Favourable step	€ 245,804 Total debts 2025: € 245,804 ▼ 32% vs 2024 (€ 360,802) Favourable step	▼ 32%
Cash	€ 233,653 Cash 2022: € 233,653 First fiscal year in the series	€ 202,361 Cash 2023: € 202,361 ▼ 13% vs 2022 (€ 233,653) Unfavourable step	€ 139,824 Cash 2024: € 139,824 ▼ 31% vs 2023 (€ 202,361) Unfavourable step	€ 70,643 Cash 2025: € 70,643 ▼ 49% vs 2024 (€ 139,824) Unfavourable step	▼ 49%
Retained profit	€ 114,143 Retained profit 2022: € 114,143 First fiscal year in the series	€ 172,543 Retained profit 2023: € 172,543 ▲ 51% vs 2022 (€ 114,143) Favourable step	€ 227,740 Retained profit 2024: € 227,740 ▲ 32% vs 2023 (€ 172,543) Favourable step	€ 284,601 Retained profit 2025: € 284,601 ▲ 25% vs 2024 (€ 227,740) Favourable step	▲ 25%
Bank debt	€ 434,022 Bank debt 2022: € 434,022 First fiscal year in the series	€ 353,276 Bank debt 2023: € 353,276 ▼ 19% vs 2022 (€ 434,022) Favourable step	€ 271,223 Bank debt 2024: € 271,223 ▼ 23% vs 2023 (€ 353,276) Favourable step	€ 187,842 Bank debt 2025: € 187,842 ▼ 31% vs 2024 (€ 271,223) Favourable step	▼ 31%
Balance sheet total	€ 681,224 Balance sheet total 2022: € 681,224 First fiscal year in the series	€ 651,617 Balance sheet total 2023: € 651,617 ▼ 4% vs 2022 (€ 681,224) Unchanged	€ 608,542 Balance sheet total 2024: € 608,542 ▼ 7% vs 2023 (€ 651,617) Unchanged	€ 550,405 Balance sheet total 2025: € 550,405 ▼ 10% vs 2024 (€ 608,542) Unchanged	▼ 10%
Employees (FTE)	-	-	1.4 Employees (FTE) 2024: 1.4 First fiscal year in the series	1.1 Employees (FTE) 2025: 1.1 ▼ 0.3 vs 2024 (1.4) Unchanged	▼ 0.3

Key figures of PHARMA 2424, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMA 2424?

What happened at PHARMA 2424 in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 7, 2026 New annual accounts for financial year 2025: profit of € 56,862 (▲ 3% vs 2024). filed late Source: NBB ↗
Jan 1, 2018 New establishment in Charleroi. KBO
Dec 23, 2011 New establishment in Charleroi. KBO
2011 Christiane Delfosse Sabine became a director. NBB
2011 Didier TENRET became a director. NBB
Dec 23, 2011 Start of the company according to the CBE. KBO

In short

From € 60,580 profit in 2022 to € 56,862 profit in 2025.

Paid € 116,497 in corporate taxes since 2022.

Best year ever: 2022, with € 60,580 profit.

On average € 177,800 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Christiane Delfosse Sabine Didier TENRET

PHARMA 2424

Union Royale Pharmaceutique de Charleroi

OFFIMED

Behind PHARMA 2424 are Christiane Delfosse Sabine and Didier TENRET. Didier TENRET is also behind Union Royale Pharmaceutique de Charleroi and OFFIMED.

Directors

According to the 2025 annual accounts

Christiane Delfosse Sabine

Director

since 2011

Didier TENRET

Director

Also active at: Union Royale Pharmaceutique de Charleroi, OFFIMED

since 2011

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Neuve 1

6061 Charleroi

2.205.898.180

Grand'Rue 2-4

6061 Charleroi

Active since 23 December 2011

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0842.084.219

VAT number

BE 0842.084.219

Registered office

Rue Neuve 1, 6061 Charleroi

Names & denominations

PHARMA 2424

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

23 December 2011

Peppol

Active · Active since 11 Dec 2025

Activities · NACE

Detailhandel in farmaceutische producten

Vervaardiging van overige farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMA 2424

Financials

What happened to PHARMA 2424?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions